- Biotech investors take note – Eli Lilly are out for deals.
- “Eli Lilly and Co aims to announce roughly one $1 billion to $5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products.“
- “It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology“
